STOCK TITAN

Annovis Bio Inc - ANVS STOCK NEWS

Welcome to our dedicated news page for Annovis Bio (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Annovis Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Annovis Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.82%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
conferences
Annovis Bio Inc

NYSE:ANVS

ANVS Rankings

ANVS Stock Data

131.03M
7.59M
24.59%
11.5%
12.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berwyn

About ANVS

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.